Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL (“good” cholesterol) to treat cardiovascular and other metabolic diseases, has raised a further €10m in a second close of its Series C financing.
This takes the total funds raised in the Series C to €50m (the first close was announced in July this year) and the total equity investment raised to date to €117m.
This latest funding came from the group IRDI-IXO and undisclosed international private investors. These investors join the shareholder base including Strategic Investment Fund (FSI), Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.
This financing will fund Phase II development of the lead Cerenis program, CER-001, an HDL-mimetic for the treatment of cardiovascular disease as well as support the development of other new HDL therapies.
The company has operations in Toulouse, France and Ann Arbor, Michigan.